Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H12Cl2N2O5 |
Molecular Weight | 323.129 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
InChI
InChIKey=WIIZWVCIJKGZOK-RKDXNWHRSA-N
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
Molecular Formula | C11H12Cl2N2O5 |
Molecular Weight | 323.129 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Chloramphenicol is a broad-spectrum antibiotic that was first isolated from
Streptomyces venezuelae in 1947. The drug was subsequently chemically synthesized. It has both a bacteriostatic and bactericidal effect; in the usual therapeutic concentrations it is bacteriostatic. Chloramphenicol is used for the treatment of serious gram-negative, gram-positive, and anaerobic infections. It is especially useful in the treatment of meningitis, typhoid fever, and cystic fibrosis. It should be reserved for infections for which other drugs are ineffective or contraindicated. Chloramphenicol, a small inhibitor of bacterial protein synthesis, is active against a variety of bacteria and readily enters the CSF. It has been used extensively in the last decades for the treatment of bacterial meningitis. In industrialized countries, chloramphenicol is restricted mostly to topical uses because of the risk of induction of aplastic anemia. However, it remains a valuable reserve antibiotic for patients with allergy to β-lactam antibiotics or with CNS infections caused by multiresistant pathogens.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: intestinal esterase Sources: https://www.iasj.net/iasj?func=article&aId=41875 |
|||
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CHLOROPTIC Approved UseIndications and Usage In accord with the concepts in the Warning Box and this section, chloramphenicolmust be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above. 1. Acute infections caused by Salmonella typhi* It is not recommended for the routine treatment of the typhoid carrier state. 2. Serious infections caused by susceptible strains in accordance with the concepts expressed above: a) Salmonella species b) H. influenzae, specially meningeal infections c) Rickettsia d) Lymphogranuloma-psittacosis group e) Various gram-negative bacteria causing bacteremia, meningitis, or other serious gram-negative infections f) Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents. 3. Cystic fibrosis regimens *In treatment of typhoid fever some authorities recommend that chloramphenicol be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse. Launch Date-5.63328E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/ |
500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CHLORAMPHENICOL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
59.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/ |
500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CHLORAMPHENICOL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/ |
500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CHLORAMPHENICOL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7463235/ |
25 mg/kg 4 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CHLORAMPHENICOL serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7463235/ |
25 mg/kg 4 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CHLORAMPHENICOL SUCCINATE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 % 4 times / day multiple, ophthalmic Recommended Dose: 0.5 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 4 times / day Sources: |
unhealthy, 0.5 - 12 years n = 163 Health Status: unhealthy Condition: acute infective conjunctivitis Age Group: 0.5 - 12 years Sex: unknown Population Size: 163 Sources: |
Other AEs: Swollen eyelid... |
0.25 g 1 times / 3 months multiple, intramuscular Recommended Dose: 0.25 g, 1 times / 3 months Route: intramuscular Route: multiple Dose: 0.25 g, 1 times / 3 months Sources: |
unhealthy, 11 years n = 1 Health Status: unhealthy Condition: infection Age Group: 11 years Sex: F Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: |
70 mg/kg 1 times / day steady, intravenous Recommended Dose: 70 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 70 mg/kg, 1 times / day Co-administed with:: (meropenem) Sources: 120 mg/kg/day |
unhealthy, 15 years n = 1 Health Status: unhealthy Condition: Cystic Fibrosis and infection Age Group: 15 years Sex: F Population Size: 1 Sources: |
Disc. AE: Hyperlactatemia... AEs leading to discontinuation/dose reduction: Hyperlactatemia (1 patient) Sources: |
3 g 1 times / day multiple, intravenous Recommended Dose: 3 g, 1 times / day Route: intravenous Route: multiple Dose: 3 g, 1 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: infection Age Group: 23 years Sex: M Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: |
2.5 g 1 times / day multiple, intravenous Recommended Dose: 2.5 g, 1 times / day Route: intravenous Route: multiple Dose: 2.5 g, 1 times / day Sources: |
unhealthy, 27 years n = 1 Health Status: unhealthy Condition: infection Age Group: 27 years Sex: F Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: |
1 g 1 times / day multiple, parenteral Recommended Dose: 1 g, 1 times / day Route: parenteral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 39 years n = 1 Health Status: unhealthy Condition: infection Age Group: 39 years Sex: M Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: |
750 mg 4 times / day steady, intravenous Recommended Dose: 750 mg, 4 times / day Route: intravenous Route: steady Dose: 750 mg, 4 times / day Co-administed with:: tobramycin Sources: nafcillin |
unhealthy, 54 years n = 1 Health Status: unhealthy Condition: purulent drainage from the surgical wound Age Group: 54 years Sex: M Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: |
4 g 1 times / day multiple, intravenous Recommended Dose: 4 g, 1 times / day Route: intravenous Route: multiple Dose: 4 g, 1 times / day Sources: |
unhealthy, 61 years n = 1 Health Status: unhealthy Condition: infection Age Group: 61 years Sex: M Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: |
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 68 years n = 1 Health Status: unhealthy Condition: infection Age Group: 68 years Sex: F Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: |
2 g 1 times / day multiple, parenteral Recommended Dose: 2 g, 1 times / day Route: parenteral Route: multiple Dose: 2 g, 1 times / day Sources: |
unhealthy, 71 years n = 1 Health Status: unhealthy Condition: infection Age Group: 71 years Sex: F Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: |
3 % 1 times / day multiple, topical Recommended Dose: 3 %, 1 times / day Route: topical Route: multiple Dose: 3 %, 1 times / day Sources: |
unhealthy, adult n = 23 Health Status: unhealthy Condition: cancer patients with (EGFRI)-induced papulopustular rash Age Group: adult Sex: unknown Population Size: 23 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Swollen eyelid | 1 patient | 0.5 % 4 times / day multiple, ophthalmic Recommended Dose: 0.5 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 4 times / day Sources: |
unhealthy, 0.5 - 12 years n = 163 Health Status: unhealthy Condition: acute infective conjunctivitis Age Group: 0.5 - 12 years Sex: unknown Population Size: 163 Sources: |
Aplastic anemia | grade 4, 1 patient Disc. AE |
0.25 g 1 times / 3 months multiple, intramuscular Recommended Dose: 0.25 g, 1 times / 3 months Route: intramuscular Route: multiple Dose: 0.25 g, 1 times / 3 months Sources: |
unhealthy, 11 years n = 1 Health Status: unhealthy Condition: infection Age Group: 11 years Sex: F Population Size: 1 Sources: |
Hyperlactatemia | 1 patient Disc. AE |
70 mg/kg 1 times / day steady, intravenous Recommended Dose: 70 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 70 mg/kg, 1 times / day Co-administed with:: (meropenem) Sources: 120 mg/kg/day |
unhealthy, 15 years n = 1 Health Status: unhealthy Condition: Cystic Fibrosis and infection Age Group: 15 years Sex: F Population Size: 1 Sources: |
Aplastic anemia | grade 5, 1 patient Disc. AE |
3 g 1 times / day multiple, intravenous Recommended Dose: 3 g, 1 times / day Route: intravenous Route: multiple Dose: 3 g, 1 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: infection Age Group: 23 years Sex: M Population Size: 1 Sources: |
Aplastic anemia | grade 4, 1 patient Disc. AE |
2.5 g 1 times / day multiple, intravenous Recommended Dose: 2.5 g, 1 times / day Route: intravenous Route: multiple Dose: 2.5 g, 1 times / day Sources: |
unhealthy, 27 years n = 1 Health Status: unhealthy Condition: infection Age Group: 27 years Sex: F Population Size: 1 Sources: |
Aplastic anemia | grade 4, 1 patient Disc. AE |
1 g 1 times / day multiple, parenteral Recommended Dose: 1 g, 1 times / day Route: parenteral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 39 years n = 1 Health Status: unhealthy Condition: infection Age Group: 39 years Sex: M Population Size: 1 Sources: |
Aplastic anemia | grade 5, 1 patient Disc. AE |
750 mg 4 times / day steady, intravenous Recommended Dose: 750 mg, 4 times / day Route: intravenous Route: steady Dose: 750 mg, 4 times / day Co-administed with:: tobramycin Sources: nafcillin |
unhealthy, 54 years n = 1 Health Status: unhealthy Condition: purulent drainage from the surgical wound Age Group: 54 years Sex: M Population Size: 1 Sources: |
Aplastic anemia | grade 5, 1 patient Disc. AE |
4 g 1 times / day multiple, intravenous Recommended Dose: 4 g, 1 times / day Route: intravenous Route: multiple Dose: 4 g, 1 times / day Sources: |
unhealthy, 61 years n = 1 Health Status: unhealthy Condition: infection Age Group: 61 years Sex: M Population Size: 1 Sources: |
Aplastic anemia | grade 4, 1 patient Disc. AE |
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 68 years n = 1 Health Status: unhealthy Condition: infection Age Group: 68 years Sex: F Population Size: 1 Sources: |
Aplastic anemia | grade 5, 1 patient Disc. AE |
2 g 1 times / day multiple, parenteral Recommended Dose: 2 g, 1 times / day Route: parenteral Route: multiple Dose: 2 g, 1 times / day Sources: |
unhealthy, 71 years n = 1 Health Status: unhealthy Condition: infection Age Group: 71 years Sex: F Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 375.9 uM] | ||||
Page: Product Information Sheet in Japanese) 18 |
no | |||
Page: Product Information Sheet in Japanese) 18 |
no | |||
Page: Product Information Sheet in Japanese) 18 |
no | |||
Page: Product Information Sheet in Japanese) 18 |
no | |||
Page: Product Information Sheet in Japanese) 18 |
no | |||
Page: Product Information Sheet in Japanese) 18 |
yes [IC50 32 uM] | |||
yes [IC50 48.1 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Therapeutic efficacy of tobramycin--a clinical and laboratory evaluation. | 1975 Dec |
|
Survey of yeast mastitis in dairy herds of small-type farms in the Lublin region, Poland. | 2001 |
|
Numerical methods for handling uncertainty in microarray data: an example analyzing perturbed mitochondrial function in yeast. | 2001 |
|
Amplification of the Escherichia coli lacZ gene in Bacillus subtilis and its expression on a by-product growth medium. | 2001 |
|
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales. | 2001 Apr |
|
The epithelial flap for photorefractive keratectomy. | 2001 Apr |
|
Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: modulatory role of testosterone via morphine clearance. | 2001 Apr |
|
Liposome-mediated DNA uptake and transient expression in Thermotoga. | 2001 Feb |
|
Phytochemical and antimicrobial properties of constituents of "Ogwu Odenigbo", a popular Nigerian herbal medicine for typhoid fever. | 2001 Feb |
|
Anti-anaerobic activity of antibacterial agents. | 2001 Feb |
|
Crystallization and preliminary X-ray diffraction analysis of the chloramphenicol acetyltransferase from Tn2424. | 2001 Feb |
|
Resistance patterns of non-O157 Shiga toxin-producing Escherichia coli (STEC) strains isolated from animals, food and asymptomatic human carriers in Switzerland. | 2001 Feb |
|
Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. | 2001 Feb |
|
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. | 2001 Feb |
|
Antibiotic susceptibility of Kingella kingae isolates from respiratory carriers and patients with invasive infections. | 2001 Feb |
|
Variable specific activity of Escherichia coli beta-galactosidase in bacterial cells. | 2001 Feb 5 |
|
A limited loss of DNA compaction accompanying the release of cytoplasm from cells of Escherichia coli. | 2001 Jan |
|
Inactivation of chloramphenicol by Staphylococcus aureus biotype C from humans & animals. | 2001 Jan |
|
Mesophyll-specific, light and metabolic regulation of the C4 PPCZm1 promoter in transgenic maize. | 2001 Jan |
|
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France. | 2001 Jan |
|
DNA circle formation in Neisseria gonorrhoeae: a possible intermediate in diverse genomic recombination processes. | 2001 Jan |
|
Adhesion to a polymeric biomaterial affects the antibiotic resistance of Staphylococcus epidermidis. | 2001 Jan |
|
New uses of older antibiotics. | 2001 Jan |
|
Molecular features determining lymphocyte reactivity in allergic contact dermatitis to chloramphenicol and azidamphenicol. | 2001 Jan |
|
Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. | 2001 Jan |
|
In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. | 2001 Jan |
|
Rocky Mountain spotted fever and pregnancy: a case report and review of the literature. | 2001 Jan |
|
Travel-associated Burkholderia pseudomallei infection (Melioidosis) in a patient with cystic fibrosis: a case report. | 2001 Jan |
|
Interaction of human aldehyde dehydrogenase with aromatic substrates and ligands. | 2001 Jan 30 |
|
[Methods of determining chloramphenicol in the workplace air]. | 2001 Jan-Feb |
|
[Lactobacillus paracasei endocarditis in an 18-yeard-old patient with trisomy 21, atrioventricular septal defect and Eisenmenger complex: therapeutic problems]. | 2001 Jan-Feb |
|
Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India. | 2001 Jan-Mar |
|
Cloning and functional analysis of a phosphopantetheinyl transferase superfamily gene associated with jadomycin biosynthesis in Streptomyces venezuelae ISP5230. | 2001 Jun |
|
External quality assessment of antimicrobial susceptibility testing in Europe. | 2001 Jun |
|
Screening of antibiotic resistant inhibitors from local plant materials against two different strains of Pseudomonas aeruginosa. | 2001 Jun |
|
[Susceptibility of non-typhi Salmonella spp. at the Galdakao Hospital (1992-1998)]. | 2001 Mar |
|
Clinical, laboratory, and epidemiologic features of murine typhus in 97 Texas children. | 2001 Mar |
|
Patterns of antibiotic resistance, serotype distribution, and patient demographics of Streptococcus pneumoniae in Hong Kong. | 2001 Mar-Apr |
|
In vitro susceptibility of Vibrio spp. isolated from the environment. | 2001 May |
|
Chromate tolerant bacteria isolated from tannery effluent. | 2001 May |
|
Neisseria meningitidis with decreased susceptibility to penicillin in Ontario, Canada 1997-2000. | 2001 May 1 |
|
Increased mitochondrial-encoded gene transcription in immortal DF-1 cells. | 2001 May 1 |
|
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas. | 2001 May-Jun |
|
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. | 2001 Spring |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15227603
The highest activity of chloramphenicol was documented for isolates of Stenotrophomonas maltophilia (76,5 % susceptible, MIC50 = 4 mg/L, MIC90 = 16 mg/L) and of Staphylococcus aureus (76,2 % susceptible, MIC50 = 8 mg/L, MIC90 = 16 mg/L).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 15:54:15 UTC 2022
by
admin
on
Fri Dec 16 15:54:15 UTC 2022
|
Record UNII |
66974FR9Q1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD10AF03
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
G01AA05
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
S03AA08
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QD06AX02
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QG01AA55
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QJ01BA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
CFR |
21 CFR 524.390
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
CFR |
21 CFR 530.41
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QS03AA08
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
D10AF03
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
D06AX02
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
CFR |
21 CFR 520.390
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
IARC | Chloramphenicol | ||
|
WHO-VATC |
QJ51BA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QJ51RB01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QS02AA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
NDF-RT |
N0000175479
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
NDF-RT |
N0000175479
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
CFR |
21 CFR 522.390
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
J01BA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
NDF-RT |
N0000175480
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QG01AA05
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
S01AA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
CFR |
21 CFR 520.390A
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
LIVERTOX |
NBK548105
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-ATC |
S02AA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
WHO-VATC |
QS01AA01
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
||
|
CFR |
21 CFR 520.390B
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D002701
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
56-75-7
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
977
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
C363
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
DTXSID7020265
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
3027
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
200-287-4
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
5959
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
DB00446
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
M3347
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | Merck Index | ||
|
CHEMBL130
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
66974FR9Q1
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
3069
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
chloramphenicol
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
Chloramphenicol
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
66974FR9Q1
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
589
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
17698
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
SUB06173MIG
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
CHLORAMPHENICOL
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
1107004
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | |||
|
2348
Created by
admin on Fri Dec 16 15:54:16 UTC 2022 , Edited by admin on Fri Dec 16 15:54:16 UTC 2022
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
MIXED INHIBITION
MAJOR
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
METABOLIC ENZYME->WEAK INHIBITOR |
COMPETITIVE INHIBITOR
Ki
|
||
|
METABOLIC ENZYME -> INHIBITOR |
COMPETITIVE INHIBITOR
Ki
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Colourless to greyish white or yellowish white, needle-like crystals or elongated plates or a crystalline powder; odourless.
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||